老年痛风患者别嘌醇与非布司他房颤风险的比较效益:倾向匹配的Medicare索赔数据分析
本研究基于2006-2012年5% Medicare老年(≥65岁)受益人队列,识别新开具别嘌醇或非布司他处方且无房颤者,采用5:1倾向匹配Cox回归比较房颤发生风险。结果发现非布司他相比别嘌醇与房颤风险升高相关(HR 1.25,95%CI 1.05-1.48),尤其非布司他80mg/日及用药前6个月风险更明显。
要点
- 老年痛风患者中,非布司他相比别嘌醇与房颤风险升高相关(HR 1.25)。
- 非布司他80mg/日相比别嘌醇<200mg/日房颤风险更高(HR 1.62)。
- 房颤风险升高在非布司他用药前6个月内最明显(HR 1.36)。
核心结论
- 在老年成人中,非布司他相比别嘌醇与房颤风险升高相关。
- 非布司他80mg/日剂量及用药前6个月房颤风险增加更明显。
研究设计与样本
- 基于2006-2012年5% Medicare受益人(≥65岁)索赔数据的回顾性队列研究。
- 识别新开具别嘌醇或非布司他处方且基线365天无相应药物及无房颤者。
- 采用5:1倾向匹配Cox回归分析比较房颤发生风险。
主要发现
- 别嘌醇和非布司他的房颤粗发生率分别为8.0/100人年和10.5/100人年。
- 倾向匹配分析中,非布司他相比别嘌醇房颤HR为1.25(95%CI 1.05-1.48)。
- 非布司他80mg/日相比别嘌醇<200mg/日房颤HR为1.62(95%CI 1.16-2.27)。
- 非布司他用药1-180天相比别嘌醇1-180天房颤HR为1.36(95%CI 1.10-1.67)。
临床怎么用
- 老年痛风患者选择降尿酸药物时,可考虑非布司他相比别嘌醇的房颤风险差异。
- 使用非布司他(尤其80mg/日)初期6个月内应关注房颤发生风险。
- 需结合患者个体情况权衡药物选择,并进一步研究验证。
局限性
- 研究结果需要重复验证。
- 基于索赔数据,可能存在未测量混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Gout is associated with a higher risk of atrial fibrillation (AF). Comparative effectiveness of allopurinol or febuxostat for reducing the AF risk is unknown, which was our study's main objective. METHODS AND RESULTS: We used the 5% Medicare Beneficiary cohort (≥65 years) from 2006 to 2012 to identify people with a new filled prescription for allopurinol or febuxostat, with a baseline period of 365 days without respective medication and without AF. We used 5:1 propensity-matched Cox regression analyses to assess whether allopurinol use differed from febuxostat use regarding the hazard ratio (HR) of incident AF. We found 25 732 eligible episodes in 23 135 beneficiaries. Of these, 2311 incident allopurinol or febuxostat use episodes (9%) ended in incident AF with crude incidence rates of 8.0 and 10.5 per 100 person-years, respectively. In propensity-matched analyses, compared with allopurinol, febuxostat was associated with higher HR of AF, 1.25 [95% confidence interval (CI) 1.05-1.48]. Compared with allopurinol <200 mg/day, febuxostat 80 mg/day was associated with significantly higher HR of AF, 1.62 (95% CI 1.16-2.27), but not febuxostat 40 mg/day or higher allopurinol doses. Compared with 1-180 days of allopurinol use, febuxostat use for 1-180 days was associated with significantly higher HR of AF, 1.36 (95% CI 1.10-1.67), but longer durations were not. CONCLUSION: Febuxostat was associated with a higher risk of AF compared with allopurinol in older adults. Increased AF risk was noted with febuxostat 80 mg/day dose and was most evident in the first 6 months of use. These findings need replication.
引用
- Singh JA, Cleveland JD. Comparative effectiveness of allopurinol and febuxostat for the risk of atrial fibrillation in the elderly: a propensity-matched analysis of Medicare claims data. Eur Heart J. 2019. PMID: 30919894. doi:10.1093/eurheartj/ehz154
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。